BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
https://sites.lifesci.ucla.edu/mbi-home/wp-content/uploads/sites/191/2015/08/UCL_MBI_logo_40.gif00galkin2https://sites.lifesci.ucla.edu/mbi-home/wp-content/uploads/sites/191/2015/08/UCL_MBI_logo_40.gifgalkin22015-09-18 10:29:262015-09-18 10:29:26BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
